Next Generation News and Research

RSS

Favorable clinical results from Endologix's Nellix technology against EVAR

Endologix, developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Sorin Group announces commercial availability of Perceval S aortic heart valve in Europe

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announces the commercial availability in Europe of the self- anchoring Perceval S aortic heart valve. The innovative next-generation valve represents the latest innovation in heart valve technology.

31 Jan 2011

NCQA to release new standards for Patient-Centered Medical Home program

On January 31, the National Committee for Quality Assurance will release new standards for its Patient-Centered Medical Home program. The new standards call on medical practices to be more patient-centered, and reinforce federal "meaningful use" incentives for primary care practices to adopt health information technology.

28 Jan 2011

NIH awards CCTSI $2.2 million grant to advance personalized medicine

A federal grant totaling $2.2 million shows how the University of Colorado School of Medicine and Anschutz Medical Campus are using technology to advance the cutting-edge field of personalized medicine -- tailoring treatments to the individual based on their genetic make-up.

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Golden Helix releases new Sequence Analysis Module for SNP & Variation Suite

Golden Helix, Inc. today announced the release of a new Sequence Analysis Module for its SNP & Variation Suite software. The new module introduces innovative tertiary analysis methods for next-generation DNA sequencing studies.

27 Jan 2011

H3 Biomedicine introduces cancer research and development operations in Cambridge

H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.

27 Jan 2011

Scientists develop copper-coated silica nanoparticles for odor removal

Scientists are reporting development of a new approach for dealing with offensive household and other odors - one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source.

27 Jan 2011

NuGEN, Caliper enter co-marketing agreement in next generation sequencing sample preparation methods

NuGEN Technologies, Inc. and Caliper Life Sciences, Inc. today announced a co-marketing agreement for the development of automated methods for next generation sequencing sample preparation on Caliper's Sciclone® NGS Workstation.

27 Jan 2011

National Center for Radioecology formed

With the renewed and growing interest in nuclear energy, radioecology experts at the U.S. Department of Energy's Savannah River National Laboratory recognized an immediate need to build the pool of radioecology expertise both here and abroad.

27 Jan 2011

NuGEN expands NGS utility for microbial transcriptome analysis with Ovation Prokaryotic RNA-Seq System

NuGEN Technologies, a leader in genomics sample preparation, expands the utility of next-generation sequencing for the analysis of microbial species and microbiome samples with its Ovation Prokaryotic RNA-Seq System.

27 Jan 2011

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Boston Scientific Corporation today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent in the treatment of patients with a single de novo atherosclerotic lesion.

27 Jan 2011

Next Generation News and Research

Favorable clinical results from Endologix's Nellix technology against EVAR

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Empire State Building, NYRR partner with MMRF for new myeloma drugs

Sorin Group announces commercial availability of Perceval S aortic heart valve in Europe

NCQA to release new standards for Patient-Centered Medical Home program

NIH awards CCTSI $2.2 million grant to advance personalized medicine

Arena reduces workforce by 25% and provides update on lorcaserin

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Golden Helix releases new Sequence Analysis Module for SNP & Variation Suite

H3 Biomedicine introduces cancer research and development operations in Cambridge

Scientists develop copper-coated silica nanoparticles for odor removal

NuGEN, Caliper enter co-marketing agreement in next generation sequencing sample preparation methods

National Center for Radioecology formed

NuGEN expands NGS utility for microbial transcriptome analysis with Ovation Prokaryotic RNA-Seq System

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Nexstim closes additional equity financing for approximately EUR 11.4 million

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

Next generation sequencing on the European growth path: Report

Bluecross awards UTHSC $2,912,751 grant to promote patient safety

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News